Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017.. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
1.2 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT2[ZAxNjVizszN NVvhVGRHPzJiaB?= M17FdWROW09? NVLoSIxwUUN3ME2wMlA1KM7:TR?= NWDD[GJpOjZzM{[2PFQ>
LS174T M4nWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH1bWJKOC53IN88US=> MV[3NkBp M3GzeGROW09? NG\qSG1KSzVyPUCuNFUh|ryP MnzGNlYyOzZ4OES=
T84 M1\zVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDoNE42KM7:TR?= NGHhZoo4OiCq NIniRZZFVVOR NYm4OXY3UUN3ME2wMlA6KM7:TR?= MVmyOlE{PjZ6NB?=
LS180 NFvUclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWmwMlUh|ryP MVG3NkBp MlTPSG1UVw>? Ml;0TWM2OD1zIN88US=> NVHIbWVpOjZzM{[2PFQ>
SW948 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDrNE42KM7:TR?= NY\idpFKPzJiaB?= NEnwe4NFVVOR MXHJR|UxRTFizszN NFriSZczPjF|Nk[4OC=>
HCT15 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXewMlUh|ryP NIrsSo84OiCq NIKxb4ZFVVOR MlvJTWM2ODxyLkSg{txO NIPrNFAzPjF|Nk[4OC=>
DLD-1 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\2W|AvPSEQvF2= NYKxZnlFPzJiaB?= MmLHSG1UVw>? MWHJR|UxRDBwODFOwG0> MlzNNlYyOzZ4OES=
MIP-101 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYi5Uo1UOC53IN88US=> MVy3NkBp MYXEUXNQ NGTkVWxKSzVyPUGg{txO MlG4NlYyOzZ4OES=
SNU1544 NVHHNnZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LyT|AvPSEQvF2= NWOye4tSPzJiaB?= MWXEUXNQ MX7JR|UxRTFizszN NWPwUpBWOjZzM{[2PFQ>
OCI-Ly10 NWjmeI1yS3m2b4TvfIlkKEG|c3H5 NVzLfFJzPzJiaB?= M{jpd2ROW09? MnTPTWM2OD1yLkC1PEDPxE1? NUnlVpV2OjV6N{izN|E>
SU-DHL2 NGTjZ|JEgXSxdH;4bYMhSXO|YYm= M1m1dlczKGh? NVXITm9PTE2VTx?= NHHKVmVKSzVyPUCuNFEh|ryP NHHhfIUzPTh5OEOzNS=>
OCI-LY7 NUHpOIpUS3m2b4TvfIlkKEG|c3H5 NGrzTpI4OiCq M1rVXmROW09? M{\kT2lEPTB;MD6wPFEh|ryP NH:1VYszPTh5OEOzNS=>
SU-DHL6 NUGyT3hIS3m2b4TvfIlkKEG|c3H5 MV[3NkBp NITyWHNFVVOR NF\MSlRKSzVyPUCuOFgzKM7:TR?= MnPoNlU5Pzh|M{G=
Jeko-1 MmjlR5l1d3SxeHnjJGF{e2G7 Ml;FO|IhcA>? NYjCNWQ3TE2VTx?= M3j4emlEPTB;MD6wNlkh|ryP MnTPNlU5Pzh|M{G=
JVM-2 M1nIdmN6fG:2b4jpZ{BCe3OjeR?= MkfRO|IhcA>? NFHrS4RFVVOR MoPaTWM2OD1yLkCxJO69VQ>? NVTiSnN{OjV6N{izN|E>
Rec-1 MXnDfZRwfG:6aXOgRZN{[Xl? M2\OT|czKGh? NWf5TWpuTE2VTx?= MYnJR|UxRTBwMEi3JO69VQ>? M2PXTlI2QDd6M{Ox
Z-138 MV7DfZRwfG:6aXOgRZN{[Xl? NIrSeGo4OiCq NGD4NG5FVVOR NEn3[HdKSzVyPUCuNFE{KM7:TR?= Mn3zNlU5Pzh|M{G=
H9 MoL5R5l1d3SxeHnjJGF{e2G7 MlPRO|IhcA>? NVrwSo5VTE2VTx?= MmTqTWM2OD1yLk[g{txO NH;TblEzPTh5OEOzNS=>
HH MWTDfZRwfG:6aXOgRZN{[Xl? M3zl[|czKGh? NX23[2lkTE2VTx?= MUnJR|UxRTBwNzFOwG0> MWqyOVg4QDN|MR?=
DND41 M13ReWN6fG:2b4jpZ{BCe3OjeR?= NEjiSZI4OiCq NUP0OXJ{TE2VTx?= MX;JR|UxRTBwMTFOwG0> M1n2[VI2QDd6M{Ox
CCL119 MnXQR5l1d3SxeHnjJGF{e2G7 NWDUfW5lPzJiaB?= NWixdWN1TE2VTx?= MVrJR|UxRTBwME[yJO69VQ>? MVOyOVg4QDN|MR?=
J.Cam 1.6 MWrDfZRwfG:6aXOgRZN{[Xl? MX:3NkBp MmjVSG1UVw>? NGjVXW5KSzVyPUCuNVA2KM7:TR?= NFvSZmEzPTh5OEOzNS=>
Sup-T1 NV\IWXlDS3m2b4TvfIlkKEG|c3H5 NVm3NZh3PzJiaB?= MmfiSG1UVw>? MX7JR|UxRTJwMUSyJO69VQ>? NUDUZXZVOjV6N{izN|E>
Tib 152 MnfPR5l1d3SxeHnjJGF{e2G7 M2LSflczKGh? NWL2SGp{TE2VTx?= NFjwfXJKSzVyPUCuPEDPxE1? M{LCR|I2QDd6M{Ox
MCF7 NWjpdHlJTnWwY4Tpc44hSXO|YYm= NXj0VJFwPSEQvF2= MlHhNlQhcA>? M3vkWmROW09? NIDMdFNKdmS3Y3XzJGczN01iYYLy[ZN1 NFLx[3YzPTh|NESwNS=>
MDA-MB-231 NITsbmxHfW6ldHnvckBCe3OjeR?= M4TROlUh|ryP MmCxNlQhcA>? M{fFfWROW09? NF\u[ldKdmS3Y3XzJGc{N01iYYLy[ZN1 NHfnN2EzPTh|NESwNS=>
MCF7 NE\mXW1HfW6ldHnvckBCe3OjeR?= NY\PUYM2PSEQvF2= M2\mV|I1KGh? M4X0O2ROW09? NEPTR2lF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy MXyyOVg{PDRyMR?=
MCF7 MVvGeY5kfGmxbjDBd5NigQ>? Mn\GOUDPxE1? NVXGTpBUOjRiaB?= NWnVPIdHTE2VTx?= NEHyTGtF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOg>? MVOyOVg{PDRyMR?=
MCF7 MoXxSpVv[3Srb36gRZN{[Xl? M2jEU|Uh|ryP NYrlb4ZsOjRiaB?= MlfTSG1UVw>? MonjSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIHP5Z4xqdiCEMR?= NFPHU2gzPTh|NESwNS=>
MCF7 MmG2SpVv[3Srb36gRZN{[Xl? NXrFSWx1PSEQvF2= MUiyOEBp NFrrRpZFVVOR NX:yWlN{UW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzOSCZYX[xM2NqeDF? Mk\tNlU5OzR2MEG=
MCF7 MlzkSpVv[3Srb36gRZN{[Xl? M1GydlUh|ryP MlXUNlQhcA>? Ml6ySG1UVw>? NWPOUFVrUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzPyCNaYCx MmKzNlU5OzR2MEG=
MDA-MB-231 NVeyTJY4TnWwY4Tpc44hSXO|YYm= NV76NGRFPSEQvF2= MlvUNlQhcA>? MnXXSG1UVw>? MVzE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{ NHP6OGwzPTh|NESwNS=>
MDA-MB-231 Ml;WSpVv[3Srb36gRZN{[Xl? NGLScowyKM7:TR?= NFT5b40zPCCq MkLYSG1UVw>? NYrmRXZVUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzJ? M3jBOlI2QDN2NECx
MDA-MB-231 NYjJRY9MTnWwY4Tpc44hSXO|YYm= MmrZOUDPxE1? MX2yOEBp NXK0SGpDTE2VTx?= Moe1SIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIHP5Z4xqdiCEMR?= NImxXVQzPTh|NESwNS=>
MDA-MB-231 NW\0ZnpMTnWwY4Tpc44hSXO|YYm= M1OyVVUh|ryP NID5TVAzPCCq M3nPeWROW09? MUfJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEKxJHdi\jFxQ3nwNS=> NFH6XHMzPTh|NESwNS=>
MDA-MB-231 M33RXWZ2dmO2aX;uJGF{e2G7 NXvzTm5OPSEQvF2= M1rnTVI1KGh? MWXEUXNQ NH63W5dKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG= MUeyOVg{PDRyMR?=
MDA-MB-231 NYP3cm9NTnWwY4Tpc44hSXO|YYm= MXu1JO69VQ>? NVL1VIwyOjRiaB?= MmfuSG1UVw>? M{W1R2lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwOVM> MWGyOVg{PDRyMR?=
MCF7 NX7vOox[SXCxcITvd4l{KEG|c3H5 Mlv5OUDPxE1? MXOyOEBp NUjoR2F1TE2VTx?= M2DvWGlv\HWlZYOgZZBweHSxdHnjJIRm[XSq NF;5cIIzPTh|NESwNS=>
MDA-MB-231 MoD6RZBweHSxc3nzJGF{e2G7 NVv1V4V3PSEQvF2= NYfjV2plOjRiaB?= MoTySG1UVw>? M1naSmlv\HWlZYOgZZBweHSxdHnjJIRm[XSq Mo[wNlU5OzR2MEG=
MCF7 MnrXSpVv[3Srb36gRZN{[Xl? NYnWd2p6OSEQvF2= MUG3NkBp M1:4b2ROW09? NEHsWGdKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= MViyOVg{PDRyMR?=
MDA-MB-231 NFHhfIlHfW6ldHnvckBCe3OjeR?= MoLoNUDPxE1? NV[zZnRQPzJiaB?= M2DJPGROW09? NInROmFKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= NEfFXIczPTh|NESwNS=>
U-2 OS MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXHOVAh|ryP NWLGTod5OjRiaB?= MXrEUXNQ M3TyR2lEPTB;MU[uOkDPxE1? MorRNlU4QTJ6MUG=
MG-63 NIG2T4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYi1NEDPxE1? MnTCNlQhcA>? NEeyRmdFVVOR NGfZSG5KSzVyPUmuOUDPxE1? MknNNlU4QTJ6MUG=
U-2 OS MVnBdI9xfG:|aYOgRZN{[Xl? MX:1JO69VQ>? MYOyOEBp MkjVSG1UVw>? NUXaVWpVUW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>? MVSyOVc6OjhzMR?=
MG-63 NEPieZdCeG:ydH;zbZMhSXO|YYm= MUC1JO69VQ>? NEH5VG8zPCCq Mmn2SG1UVw>? NEXVeoxKdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp NYGzNlY6OjV5OUK4NVE>
U-2 OS M4jjbGZ2dmO2aX;uJGF{e2G7 M3v2e|Uh|ryP NX3sWlZYOjRiaB?= MlvBSG1UVw>? MoHWVJJwdW:2ZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp M{O0NFI2Pzl{OEGx
MG-63 NFrLPZZHfW6ldHnvckBCe3OjeR?= MUi1JO69VQ>? MXSyOEBp NFuwN4ZFVVOR NIfP[FhRem:vb4Tld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? MoW4NlU4QTJ6MUG=
PANC-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVG1NEDPxE1? MmHpNlQhcA>? M131bGROW09? MYnJR|UxRTdwMTFOwG0> NXXhWoN[OjV4M{KyNlU>
BxPC-3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrvUZlxPTBizszN MX[yOEBp Mm[0SG1UVw>? NYPQXZZZUUN3ME22Mlgh|ryP NEjjRpUzPTZ|MkKyOS=>
PANC-1 NFPXbm5HfW6ldHnvckBCe3OjeR?= MWq1JO69VQ>? MYmyOEBp M1\OUWROW09? MmnhTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckBIOi:PIIDoZZNm NF3xS3UzPTZ|MkKyOS=>
BxPC-3 MonwSpVv[3Srb36gRZN{[Xl? MWi1JO69VQ>? NEnRXWszPCCq MXrEUXNQ NWT5fVFjUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn MmjUNlU3OzJ{MkW=
PANC-1 NIfGeYxHfW6ldHnvckBCe3OjeR?= M2HQV|Uh|ryP NYe5PXY2OjRiaB?= NUjzfpltTE2VTx?= NYXXS|VSUW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? NI\CbHAzPTZ|MkKyOS=>
BxPC-3 MUnGeY5kfGmxbjDBd5NigQ>? M1nIXlUh|ryP M1\oSVI1KGh? NVPFVY54TE2VTx?= MYjJcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> NG\MeFEzPTZ|MkKyOS=>
SKOV3 NHnpeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ro[|ExOCEQvF2= MV[yOEBp Mlj0SG1UVw>? NXLhSJFPUUN3ME2yNE41QCEQvF2= MmDwNlU3OjR5NUC=
OVCAR4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzOUok3OTByIN88US=> NUHjRoxGOjRiaB?= M4DPSGROW09? MXzJR|UxRTJ{LkGzJO69VQ>? MoXnNlU3OjR5NUC=
SKOV3 NHq5Uo1HfW6ldHnvckBCe3OjeR?= NVviTmdqPSEQvF2= M3\ZbFczKGh? MV7EUXNQ MknaTY5lfWOnczDHNk9OKGG{cnXzeC=> MmPINlU3OjR5NUC=
OVCAR4 NEWyfJlHfW6ldHnvckBCe3OjeR?= M335NFUh|ryP NUS2SFRwPzJiaB?= NIfWeXFFVVOR MmXYTY5lfWOnczDHNk9OKGG{cnXzeC=> Ml;rNlU3OjR5NUC=
SKOV3 NGrtXphCeG:ydH;zbZMhSXO|YYm= NWfmUlFuPSEQvF2= MonUNlQhcA>? NXnV[nRjTE2VTx?= NIjxUoJKdmS3Y3XzJIFxd3C2b4Ppdy=> NGfnVJAzPTZ{NEe1NC=>
OVCAR4 M1HlfGFxd3C2b4Ppd{BCe3OjeR?= M1fpNVUh|ryP MlrjNlQhcA>? NVjrPGJkTE2VTx?= NUnpcZU5UW6mdXPld{BieG:ydH;zbZM> NVvo[XZCOjV4MkS3OVA>
AGS MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVX0Z|llOjVizszN M4HneVI1KGh? NUmzPIdyTE2VTx?= NIX6dJFKSzVyPUG5MlA6KM7:TR?= M17y[VI2PjB7OUKz
NCI-N78 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nZcVI2KM7:TR?= M2TBTFI1KGh? NH2xU5pFVVOR MVnJR|UxRTJ4LkOzJO69VQ>? MnzmNlU3ODl7MkO=
AGS MnPmRZBweHSxc3nzJGF{e2G7 M4rNe|Uh|ryP NUSzOVM1OjRiaB?= MWHEUXNQ NXvWfWtqUW6mdXPld{BieG:ydH;zbZM> NXXPd|llOjV4MEm5NlM>
NCI-N78 M1PEfmFxd3C2b4Ppd{BCe3OjeR?= NFvhZWI2KM7:TR?= MmD1NlQhcA>? NVrsOGdGTE2VTx?= MYjJcoR2[2W|IHHwc5B1d3Orcx?= NEm0R2MzPTZyOUmyNy=>
AGS NIH5UJJHfW6ldHnvckBCe3OjeR?= M33yUVUh|ryP NUX1eXd4OjRiaB?= NI\JTJFFVVOR NID0UGxKdmS3Y3XzJJRp\SCjdYTvdIhi\3l? NUTGNGlDOjV4MEm5NlM>
NCI-N78 NH\JbXBHfW6ldHnvckBCe3OjeR?= NEDadJI2KM7:TR?= NWDhVJJoOjRiaB?= MofvSG1UVw>? NX61enRVUW6mdXPld{B1cGViYYX0c5Bp[We7 MVqyOVYxQTl{Mx?=
HSC-3 M3HXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjkU3h7OSEQvF2= NHW3fYI1QCCq NILWbnpKSzVyPUCuOVQh|ryP M2rSZVI2OzZ4MUSz
GB30 NGrjfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr6NUDPxE1? MYq3JIQ> MV\EUXNQ NYDMZVhVUUN3ME2wMlAyOSEQvF2= MUSyOVExPjR{OB?=
GB9 NX\oc5pUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXmeGgyKM7:TR?= Mk\zO{Bl NGnEcYdFVVOR NXr1boRoUUN3ME2wMlAzPCEQvF2= MkWwNlUyODZ2Mki=
GB169 NG\hZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrrOXpXOSEQvF2= M{Dhc|ch\A>? MnnjSG1UVw>? MX7JR|UxRTBwMEOyJO69VQ>? M3zMR|I2OTB4NEK4
T24 NWPM[4lLTnWwY4Tpc44hSXO|YYm= Ml:wNUDPxE1? MnO5OFghcA>? M2HoemROW09? M1\icGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MkjKNlM1ODN4M{O=
RT4 MVLGeY5kfGmxbjDBd5NigQ>? NI\oRWIyKM7:TR?= NYfrZoV{PDhiaB?= MYnEUXNQ NYjBfllmUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MmTXNlM1ODN4M{O=
UM-UC-3 MYjGeY5kfGmxbjDBd5NigQ>? NHfGfGkyKM7:TR?= MWW0PEBp NHW4VXFFVVOR M2XnPGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= NVK1RY1HOjN2MEO2N|M>
T24 Mnv6RZBweHSxc3nzJGF{e2G7 MUmzMlE3KM7:TR?= NGGyZ3o6PiCq NFvOXoVFVVOR MkfhTWM2OD1yLkCzNFYh|ryP M{PzNFI{PDB|NkOz
RT4 M2SybWFxd3C2b4Ppd{BCe3OjeR?= MmXxN{4yPiEQvF2= Mlv6PVYhcA>? NX3Q[IZnTE2VTx?= NXX5bWZIUUN3ME2wMlEyQThizszN MYeyN|QxOzZ|Mx?=
UM-UC-3 NUno[mZwSXCxcITvd4l{KEG|c3H5 MXyzMlE3KM7:TR?= NWnxeoZtQTZiaB?= MXzEUXNQ NYXOTHFTUUN3ME2wMlA1PDlizszN MUSyN|QxOzZ|Mx?=
OVCAR-5 M{\uNmZ2dmO2aX;uJGF{e2G7 MnjsOVAhdk1? MljCTY5pcWKrdIOgZ4VtdCCvaXfyZZRqd25? M2joWFI{OzN2M{K3
SKOV3ip2 Ml;ESpVv[3Srb36gRZN{[Xl? MVG1NEBvVQ>? MonRTY5pcWKrdIOgZ4VtdCCvaXfyZZRqd25? NWnHOGZqOjN|M{SzNlc>
S462 MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PqW|ExOCEQvF2= M3LIclczKGh? MkDjSG1UVw>? NGfEcmhCfHSnboXheIV{KGOnbHyg[5Jwf3Sq MnvtNlM{OjhzMUS=
2884 NGq4SGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqxNFAh|ryP MlzrO|IhcA>? NVzVdXh3TE2VTx?= NI\4[npCfHSnboXheIV{KGOnbHyg[5Jwf3Sq M3fJSVI{OzJ6MUG0
2885 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfhNVAxKM7:TR?= NILVXpI4OiCq NYfBV3k6TE2VTx?= NFLzOVZCfHSnboXheIV{KGOnbHyg[5Jwf3Sq MXKyN|MzQDFzNB?=
CRL-2396 NEPuPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\NNVAxKM7:TR?= NIXSTnd4[XSnch?= NILmb4RKSzVyPUCuNFkzKM7:TR?= NYrSOIRKOjNzNUO1NlQ>
TIB-48 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2xNFAh|ryP MnXIe4F1\XJ? NIrBcnBKSzVyPUCuNFg5KM7:TR?= NFjwdFgzOzF3M{WyOC=>
CRL-2396 MWDDfZRwfG:6aXOgRZN{[Xl? NUjBeo41OSEQvF2= MmTBOFghcA>? Mojxe4F1\XJ? MWHJcoR2[2W|IHHwc5B1d3Orcx?= NYrKdZZUOjNzNUO1NlQ>
TIB-48 M4T4bmN6fG:2b4jpZ{BCe3OjeR?= M3rlOVEh|ryP MUO0PEBp NUHsUI5lf2G2ZYK= Ml;KTY5lfWOnczDhdI9xfG:|aYO= M2fCblI{OTV|NUK0
AGS NXrVcYpTS3m2b4TvfIlkKEG|c3H5 MofTNE42KM7:TR?= NHPiU|AzPCCq M1;SdWROW09? MnmzSIVkemWjc3XzJINmdGxic4Xyeol3[Wx? NYW1dHE3OjJ7N{K2NVE>
FLO-1 MWTDfZRwfG:6aXOgRZN{[Xl? MYqwMlUh|ryP M4jSUVI1KGh? M1zvfmROW09? NVPYfXRQTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy= M{nEWVIzQTd{NkGx
OE33 M37QNWN6fG:2b4jpZ{BCe3OjeR?= NUPwNmNJOC53IN88US=> MWSyOEBp MnniSG1UVw>? MX;E[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? NGLwOYozOjl5Mk[xNS=>
SKLMS M1\4cGN6fG:2b4jpZ{BCe3OjeR?= MmTGO|Uhdk1? Mn7jPVYhcA>? NYjCbWhGUW6mdXPld{BieG:ydH;zbZM> MX:yNlgzOTl7Nx?=
Leio285 NV;1Tld1S3m2b4TvfIlkKEG|c3H5 M3ixOFc2KG6P NHXDT5g6PiCq M1;R[2lv\HWlZYOgZZBweHSxc3nz MlPtNlI5OjF7OUe=
Mes-Sa MYrDfZRwfG:6aXOgRZN{[Xl? NHfI[5M4PSCwTR?= MWq5OkBp NVHPfJVJUW6mdXPld{BieG:ydH;zbZM> MWmyNlgzOTl7Nx?=
DAOY MkHOR5l1d3SxeHnjJGF{e2G7 MWSxNEDPxE1? NUGxbVlVPzJiaB?= MVTEUXNQ MoLETWM2OD1yLkC0JO69VQ>? M3vzZVIzPjZ7M{O1
IMR32 M1\kOWN6fG:2b4jpZ{BCe3OjeR?= MnLmNVAh|ryP MkCyO|IhcA>? NXzy[WN2TE2VTx?= NFLGZllKSzVyPUCuNFMh|ryP MlTZNlI3Pjl|M{W=
Molt-4 NUDsNYppS3m2b4TvfIlkKEG|c3H5 MUmxNEDPxE1? NFTw[Gc4OiCq MlX1SG1UVw>? NELs[3pKSzVyPUCuNFIh|ryP MlW5NlI3Pjl|M{W=
MOLM-13 NYHpT3E{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\vS4tuOyEQvF2= NILjTYg4OiCq NYPqepZ{TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> MUmyNlQ5QDJ2OR?=
HL-60 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDld4o{KM7:TR?= M3\sXVczKGh? MUnEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MYeyNlQ5QDJ2OR?=
MV4-11 NIP6fFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi1WFY{KM7:TR?= Mnu1O|IhcA>? NHTuc2VFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NEHkZlAzOjR6OEK0PS=>
SKM-1 NEXRUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fqWlMh|ryP M1juXlczKGh? Ml3ZSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= M{fPe|IzPDh6MkS5
SH2 M1HpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nhUFMh|ryP MVW3NkBp NV2xV|RqTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> NGjx[ZozOjR6OEK0PS=>
NOMO-1 Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37OVlMh|ryP NEHhVJk4OiCq MkHpSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= M2LpclIzPDh6MkS5
OCL-AML2 NXq2Z3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor3N{DPxE1? M3HxbVczKGh? M{PsOGRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NXziUVU1OjJ2OEiyOFk>
PL-21 M4n3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXizJO69VQ>? MXe3NkBp NITnXGlFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NHHLUIwzOjR6OEK0PS=>
KG-1 NVrBWVRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDIU3k{KM7:TR?= MmG4O|IhcA>? NFfNXHdFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MmTONlI1QDh{NEm=
A172 NGLRfmdEgXSxdH;4bYMhSXO|YYm= MojWNVAxKM7:TR?= NECzcpczPCCq NI\DXJJFVVOR NVe3[mxmUUN3ME2wMlEzOCEQvF2= NUK4OmtwOjJ{N{SzPVk>
U87 NHT3OoVEgXSxdH;4bYMhSXO|YYm= NX7mdpNPOTByIN88US=> MnnLNlQhcA>? MXTEUXNQ MofQTWM2OD1yLkGwOUDPxE1? NWDtR|B4OjJ{N{SzPVk>
U251 M1jOSmN6fG:2b4jpZ{BCe3OjeR?= NX7jdYpwOTByIN88US=> NUfyNGtxOjRiaB?= NEDW[4JFVVOR NYrQXVBIUUN3ME2wMlExOCEQvF2= Mmf2NlIzPzR|OUm=
T98 NX24Ro83S3m2b4TvfIlkKEG|c3H5 MUWxNFAh|ryP MV2yOEBp NVzSb|lTTE2VTx?= Ml\OTWM2OD1yLkGyOUDPxE1? NIfQZVkzOjJ5NEO5PS=>
LN18 NXuyUpFJS3m2b4TvfIlkKEG|c3H5 MmflNVAxKM7:TR?= NY\Idm5ZOjRiaB?= MnzqSG1UVw>? MoPvTWM2OD1yLkKxNEDPxE1? NWT0RoJ[OjJ{N{SzPVk>
LN443 M{jpT2N6fG:2b4jpZ{BCe3OjeR?= MYCxNFAh|ryP MnvKNlQhcA>? MXvEUXNQ MnPyTWM2OD1yLkKyNEDPxE1? MnW0NlIzPzR|OUm=
HF66 MX7DfZRwfG:6aXOgRZN{[Xl? M1izfVExOCEQvF2= MkCwNlQhcA>? M2DMNmROW09? NXXNWmtlUUN3ME2wMlIzPSEQvF2= NWH4T4oyOjJ{N{SzPVk>
HF2303 NGLXVphEgXSxdH;4bYMhSXO|YYm= NW\M[ppyOTByIN88US=> M4\0S|I1KGh? NXv1cnRLTE2VTx?= MlHpTWM2OD1yLkC2NEDPxE1? MWOyNlI4PDN7OR?=
HF2359 MYTDfZRwfG:6aXOgRZN{[Xl? NYi5OpdXOTByIN88US=> M4nHdFI1KGh? NYn6RmJ1TE2VTx?= MVvJR|UxRTBwME[wJO69VQ>? MmLuNlIzPzR|OUm=
HF2414 MWPDfZRwfG:6aXOgRZN{[Xl? MXSxNFAh|ryP MXGyOEBp MmKxSG1UVw>? NYL0WXF2UUN3ME2wMlA5OCEQvF2= M1zmblIzOjd2M{m5
A-673 M2DZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn4fFlQOTBizszN NXHwW2h1QTZiaB?= MkjZSG1UVw>? NH\oO3FKSzVyPUCuNFMzKM7:TR?= M4jWRVIyPDR6NUmx
TC-32 NWrMPY1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyxNEDPxE1? MV:5OkBp MUPEUXNQ M3H5WmlEPTB;MD6wN|kh|ryP M2PuWFIyPDR6NUmx
TC-71 MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLSW3VsOTBizszN M332S|k3KGh? NXXDVVdITE2VTx?= NGj5fZJKSzVyPUCuNVAzKM7:TR?= NGG4dIIzOTR2OEW5NS=>
SK-N-MC MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37mWlExKM7:TR?= MVu5OkBp MYrEUXNQ MX3JR|UxRTBwMEeyJO69VQ>? MofPNlE1PDh3OUG=
CHLA-9 NXS2bHhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyxNEDPxE1? MY[5OkBp MUHEUXNQ MYnJR|UxRTBwMEG4JO69VQ>? NFXZeJkzOTR2OEW5NS=>
CHLA-10 NF\UZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TmUFExKM7:TR?= NIXiOIY6PiCq NU\neoExTE2VTx?= MWfJR|UxRTBwME[wJO69VQ>? NX[yUXV[OjF2NEi1PVE>
CHLA-25 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PQe|ExKM7:TR?= NXPUWXM3QTZiaB?= NHnlVIlFVVOR M4DpbGlEPTB;MD6xOlgh|ryP MnrqNlE1PDh3OUG=
CHLA-32 M4\DeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DEd|ExKM7:TR?= MofBPVYhcA>? MnrjSG1UVw>? MV7JR|UxRTBwMUO2JO69VQ>? NGW2boEzOTR2OEW5NS=>
CHLA-56 NX3qdFJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULSR3V1OTBizszN MoPvPVYhcA>? Ml3zSG1UVw>? NHmyWW9KSzVyPUGwJO69VQ>? NV;YRWs2OjF2NEi1PVE>
CHLA-258 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICwPW8yOCEQvF2= NHXEeFc6PiCq NHnpXJVFVVOR NGKzc5VKSzVyPUCuNVMzKM7:TR?= M3G5cFIyPDR6NUmx
COG-E-352 MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVixNEDPxE1? M4TnUVk3KGh? MkPQSG1UVw>? M2XRU2lEPTB;MD6wOFMh|ryP MYeyNVQ1QDV7MR?=
CHLA-90 M3nLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKxNEDPxE1? MXy5OkBp NIPYdFhFVVOR NHywfVNKSzVyPUCuNFYyKM7:TR?= NXrs[XM4OjF2NEi1PVE>
CHLA-119 NWnZWoc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPZdJEyOCEQvF2= MX25OkBp M1zEXWROW09? M4fwNGlEPTB;MD6wNlIh|ryP MVeyNVQ1QDV7MR?=
CHLA-122 NX;BPYVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L4NVExKM7:TR?= MnToPVYhcA>? NYHERnhUTE2VTx?= MYTJR|UxRTBwMEG5JO69VQ>? M{fCflIyPDR6NUmx
CHLA-136 MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf0e|cyOCEQvF2= NXfLW21ZQTZiaB?= M4nsOWROW09? MXzJR|UxRTBwMEO5JO69VQ>? MkDDNlE1PDh3OUG=
CHLA-140 NXjVblZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSxNEDPxE1? MlLTPVYhcA>? NWT2boVlTE2VTx?= M2rLUGlEPTB;MD6wNlYh|ryP M1yzeVIyPDR6NUmx
LA-N-6 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGqzOm0yOCEQvF2= MlzmPVYhcA>? NGLLXYxFVVOR M4WxWWlEPTB;MD6wOVQh|ryP MViyNVQ1QDV7MR?=
NB-1643 NF3VOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzKfYMyOCEQvF2= NUjQZZJXQTZiaB?= NYLoN2xxTE2VTx?= Mn\5TWM2OD1yLkCzO{DPxE1? M2qwSVIyPDR6NUmx
NB-EBc1 NHz1b4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKxNEDPxE1? NVzQVW1kQTZiaB?= MWTEUXNQ MUDJR|UxRTBwMEWwJO69VQ>? MUGyNVQ1QDV7MR?=
SK-N-BE-1 MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGxNEDPxE1? MYS5OkBp NHr5UGlFVVOR MX7JR|UxRTBwMEK4JO69VQ>? NG\lRlgzOTR2OEW5NS=>
SK-N-BE-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXexNEDPxE1? M4DaZlk3KGh? Moe3SG1UVw>? NUfYNI0yUUN3ME2wMlA{PiEQvF2= NVWzSWZXOjF2NEi1PVE>
SMS-KAN M{XXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOxNEDPxE1? M3LZUFk3KGh? MXvEUXNQ MWXJR|UxRTBwMEO0JO69VQ>? MUGyNVQ1QDV7MR?=
SMS-KANR MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHUPHNqOTBizszN NY\0ZmdiQTZiaB?= Ml;QSG1UVw>? NFrIZYJKSzVyPUCuNFI3KM7:TR?= NUHWdpU2OjF2NEi1PVE>
SMS-KCN MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrMWZIyOCEQvF2= MV65OkBp M2PlTGROW09? M2\I[2lEPTB;MD6wNVkh|ryP NGTidVIzOTR2OEW5NS=>
SMS-KCNR NUK1ZmdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPpToN1OTBizszN MVG5OkBp M2nsNGROW09? M130W2lEPTB;MD6wNVAh|ryP NFr1V2YzOTR2OEW5NS=>
SMS-LHN NFu5OHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33QTlExKM7:TR?= NF\BS|g6PiCq NXPGXWJ5TE2VTx?= M1TWcmlEPTB;MD6wN|Ih|ryP NH3mPIEzOTR2OEW5NS=>
SMS-MSN NXmxeJJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[xNEDPxE1? NEW0OYo6PiCq NHizemFFVVOR NU[0[YlmUUN3ME2wMlAzOiEQvF2= MUKyNVQ1QDV7MR?=
SMS-SAN M1m2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLkXIdLOTBizszN NH:1TIo6PiCq NIrHVYZFVVOR NEOzZ5lKSzVyPUCuNFIxKM7:TR?= MmDyNlE1PDh3OUG=
Granta-4 MUfDfZRwfG:6aXOgRZN{[Xl? NIrCd4EyOCEQvF2= NEC4UG84KGR? NILYOYhKSzVyPUCuNFQxKM7:TR?= NV;qSW4xOjF{OUG4Olc>
DB NHTjOFhEgXSxdH;4bYMhSXO|YYm= Ml\JNVAh|ryP MVS3JIQ> Mly2TWM2OD1yLkC0NkDPxE1? MUiyNVI6OTh4Nx?=
RL MonVR5l1d3SxeHnjJGF{e2G7 MYixNEDPxE1? NGTkOZY4KGR? Moi4TWM2OD1yLkCxOUDPxE1? M2TpPFIyOjlzOE[3
K562 NYfKVm5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vZZlExKM7:TR?= MV65OkBp MmDrTWM2OD1yLkC4O{DPxE1? M4XuU|IyODlzNkOz
LAMA-84 NFv4OXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxNEDPxE1? NFLrRnY6PiCq M4\uemlEPTB;MD6wOVch|ryP NYXhclV{OjFyOUG2N|M>
MM15 M{L4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDXRlY1KM7:TR?= NHHUZmk4OiCq MV\EUXNQ M4DRVWlEPTB;MD6xN{DPxE1? NXfufppVOjB|OEK4OFQ>
OPM1 Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv6cGh[PCEQvF2= MkK3O|IhcA>? MmTRSG1UVw>? NWXlTVV5UUN3ME2wMlA{KM7:TR?= NIK3b2YzODN6Mki0OC=>
RPM1 Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O4U|Qh|ryP NFLpUYs4OiCq MUTEUXNQ MkS3TWM2OD1zMD6zNkDPxE1? NWrUPYg{OjB|OEK4OFQ>
INA6 M{fpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlftOEDPxE1? MVu3NkBp MoW1SG1UVw>? NWnZVIdPUUN3ME2wMlAxOiEQvF2= MnfMNlA{QDJ6NES=
OPM2 MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvIeYk1KM7:TR?= MUm3NkBp M4jTPWROW09? MlPMTWM2OD12LkO3JO69VQ>? NETuTFUzODN6Mki0OC=>
MM1R M{f1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[wdFM1KM7:TR?= M4XWbFczKGh? M4LufWROW09? NGK1PFFKSzVyPUGuOlgh|ryP NHj0SmMzODN6Mki0OC=>
DOX40 M1fXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;V[YNOPCEQvF2= MWC3NkBp NEPKOZBFVVOR NUfMXW5iUUN3ME21MlQ5KM7:TR?= Mm\iNlA{QDJ6NES=
LR5 NYDkPG5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX60JO69VQ>? Mn\xO|IhcA>? NVTvRWlnTE2VTx?= MnfQTWM2OD1{LkWzJO69VQ>? NEjZWYEzODN6Mki0OC=>
U266 NV7Wd2VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUC0JO69VQ>? MnO0O|IhcA>? NF[xcZZFVVOR M1fPTWlEPTB;MT60N{DPxE1? MXSyNFM5Ojh2NB?=
RD NGLZUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjJNVAh|ryP NVTTXFRSQTZiaB?= NXrNPGhVUUN3ME2wMlIzQCEQvF2= Mm\zNlAyODh|M{i=
Rh41 M4XVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nyXVExKM7:TR?= NVzpdWt4QTZiaB?= MYfJR|UxRTBwMEmwJO69VQ>? MVqyNFExQDN|OB?=
Rh30 MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPvXXY{OTBizszN M3S0dlk3KGh? NI\rN5dKSzVyPUCuNlMxKM7:TR?= NHzIcVEzODFyOEOzPC=>
BT-12 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH5RoJJOTBizszN NILVTlA6PiCq M3mxdGlEPTB;MD6wOlAh|ryP NGfnUmUzODFyOEOzPC=>
CHLA-266 NV7jOlFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnroNVAh|ryP M1LIXFk3KGh? M4O5WWlEPTB;MD6wO|Ih|ryP M2TISlIxOTB6M{O4
TC-71 Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{L0blExKM7:TR?= NHe1WIc6PiCq MYrJR|UxRTBwMUCyJO69VQ>? M1rUWFIxOTB6M{O4
SJ-GBM2 NUjzOXYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfrPJIyOCEQvF2= M4Tj[|k3KGh? NEfuc21KSzVyPUCuNFUxKM7:TR?= M1q0PVIxOTB6M{O4
NALM-6 M13NPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKxNEDPxE1? MV25OkBp MlTwTWM2OD1yLkC2NkDPxE1? M3jjZlIxOTB6M{O4
COG-LL-317 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq4NVAh|ryP M3jw[lk3KGh? MmHTTWM2OD1yLkC0O{DPxE1? NWjseFJJOjBzMEizN|g>
RS4-11 M3XJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fWN|ExKM7:TR?= M3nzS|k3KGh? M4\FfWlEPTB;MD6wNVgh|ryP Mk\YNlAyODh|M{i=
MOLT-4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHjNYkyOCEQvF2= NVjnV5Z[QTZiaB?= M2fuWmlEPTB;MD6wNlYh|ryP M{PPSFIxOTB6M{O4
CCRF-CEM M1vNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W3eVExKM7:TR?= MXq5OkBp NWL6[JQ{UUN3ME2wMlA6PCEQvF2= MnTJNlAyODh|M{i=
Kasumi-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmxNEDPxE1? NFu3VJY6PiCq M4nKNWlEPTB;MD6xNFMh|ryP NWXLT3B5OjBzMEizN|g>
Karpas-299 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVSxNEDPxE1? MUO5OkBp MWrJR|UxRTBwMEO4JO69VQ>? MmHKNlAyODh|M{i=
Ramos-RA1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jGWVExKM7:TR?= NYXkdZcyQTZiaB?= MkXVTWM2OD1yLkGyO{DPxE1? MmjjNlAyODh|M{i=

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
15% Captisol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Related Antibodies

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID